Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century (Q37360066)

19 August 2017

Population level survival of patients with chronic myelocytic leukemia in Germany compared to the US in the early 21st century (English)

1 reference

19 August 2017

0 references

1 reference

Benjamin Barnes

2

0 references

Nora Eisemann

Nora Eisemann

4

0 references

Lina Jansen

Lina Jansen

3

0 references

Klaus Kraywinkel

Klaus Kraywinkel

9

0 references

Hermann Brenner

Hermann Brenner

10

0 references

Bernd Holleczek

8

Bernd Holleczek

1 reference

PMCID

3848850

GEKID Cancer Survival Working Group

19 August 2017

11

GEKID Cancer Survival Working Group

1 reference

19 August 2017

5

Katharina Emrich

1 reference

19 August 2017

6

Adam Gondos

1 reference

19 August 2017

1

Dianne Pulte

1 reference

19 August 2017

Stefan Hentschel

7

1 reference

19 August 2017

16 September 2013

1 reference

Journal of Hematology & Oncology

19 August 2017

1 reference

19 August 2017

6

1 reference

19 August 2017

70

1 reference

19 August 2017

1

1 reference

Creative Commons Attribution 2.0 Generic

19 August 2017

start time

16 September 2013

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1756-8722-6-70

0 references

cites work

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Success story of targeted therapy in chronic myeloid leukemia: a population-based study of patients diagnosed in Sweden from 1973 to 2008

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Age disparity in the dissemination of imatinib for treating chronic myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Up-to-date and precise estimates of cancer patient survival: model-based period analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Period analysis for 'up-to-date' cancer survival data: theory, empirical evaluation, computational realisation and applications

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

A computer program for period analysis of cancer patient survival

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Projecting SEER cancer survival rates to the US: an ecological regression approach

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Basic issues in estimating and comparing the survival of cancer patients.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Marrow transplantation for chronic myeloid leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Effects of vitamin A on survival in patients with chronic myelogenous leukemia: a SWOG randomized trial

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Survival from common and rare cancers in Germany in the early 21st century

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Recent trends in long-term survival of patients with chronic myelocytic leukemia: disclosing the impact of advances in therapy on the population level

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Interpreting international comparisons of cancer survival: the effects of incomplete registration and the presence of death certificate only cases on survival estimates.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. The German CML Study Group.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3848850

Long-term survival in chronic myelocytic leukemia after a first primary malignancy

2 October 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-6-70

Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370 000 cancer patients in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-6-70

Up-to-Date Long-Term Survival Curves of Patients With Cancer by Period Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-6-70

Deriving Valid Population-Based Cancer Survival Estimates in the Presence of Nonnegligible Proportions of Cancers Notified by Death Certificates Only

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1756-8722-6-70

Use of period analysis for providing more up-to-date estimates of long-term survival rates: empirical evaluation among 370,000 cancer patients in Finland

21 January 2018

1 reference

12 December 2020

United States life tables, 2000

1 reference

12 December 2020

An alternative approach to monitoring cancer patient survival

1 reference

12 December 2020

Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group

1 reference

12 December 2020

[Chronic myeloid leukemia in health regions 1, 3, 4 and 5 during the period 1990-96]

1 reference

12 December 2020

A global comparison regarding patient access to cancer drugs

1 reference

12 December 2020

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study

1 reference

12 December 2020

Up-to-date long-term survival curves of patients with cancer by period analysis

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-8722-6-70

1 reference

PMCID

3848850

Dimensions Publication ID

19 August 2017

0 references

1 reference

19 August 2017

1 reference

PMCID

3848850